*From the Authors*:

We thank Dr. Tang and colleagues for their interest in our paper ([@bib1]). We agree that positron emission tomography (PET) may be able to detect pulmonary artery hypertension (PAH) at an early stage, before overt hemodynamic changes become evident. Our study demonstrated that infiltration of macrophages into the lung precedes the onset of any increase in pulmonary artery pressure, which is in line with several previous animal studies suggesting that inflammation is an early driver of PAH pathogenesis ([@bib2]). Although there are no conclusive data regarding whether inflammation occurs earlier than the increase of pulmonary artery pressure in human PAH, several lines of evidence support the concept that inflammation plays a pivotal role in the pathobiology of human PAH as well ([@bib3]), suggesting that PET has a great potential to detect possible subclinical changes in the lungs of patients with PAH. However, as the authors sharply pointed out, PET may not be an adequate modality to screen for rare disorders such as PAH, considering the limited accessibility to PET. Exposure to radiation is another important issue that should be taken into account when considering PET as a screening tool for early detection of PAH.

We completely agree with the suggestion by Dr. Tang and colleagues that a more clinically realistic target population for PAH screening using PET would be individuals at high risk of developing this devastating disease, particularly those with chronic inflammatory conditions, such as certain connective tissue diseases ([@bib4]), sickle cell anemia ([@bib5]), and HIV infection ([@bib6]). In particular, considering that the prevalence of PAH is ∼10% in patients with systemic sclerosis, with a 50% mortality rate within 3 years of a PAH diagnosis ([@bib7], [@bib8]), these patients may represent a population in which PAH screening with PET would provide the greatest benefit and could be justified. Indeed, when we preliminarily performed ^68^Ga-2-(p-isothiocyanatobenzyl)-1,4,7-triazacyclononane1,4,7-triacetic acid mannosylated human serum albumin (^68^Ga-NOTA-MSA) PET in two patients with systemic sclerosis and no evidence of PAH on right heart catheterization, the lung-to-reference ratio of ^68^Ga-NOTA-MSA uptake was 0.215 and 0.221, respectively, which was higher than that observed in the normal subjects or those with pulmonary hypertension by left heart disease, but lower than that in the patients with primary PAH. We are enrolling more patients with systemic sclerosis and serial echocardiographic assessments to address this issue, aiming to explore the clinical value of ^68^Ga-NOTA-MSA PET for predicting possible PAH.

Another important issue is the diagnostic specificity of ^68^Ga-NOTA-MSA PET for PAH, which was also raised by Dr. Tang and colleagues. It is crucial to keep in mind that the increased lung uptake of ^68^Ga-NOTA-MSA is not necessarily equal to the increased infiltration of macrophages into the pulmonary vessels. As the authors mentioned, the expression of mannose receptor is not confined to macrophages. Because it is also expressed by smooth muscle cells in the trachea ([@bib9]), as well as in the lymphatic endothelium ([@bib10]), it is unclear whether the increased uptake of ^68^Ga-NOTA-MSA is derived from macrophages or other cells, or both. Although we do not have direct evidence for this, it has been reported that the expression of mannose receptor is increased in peripheral blood mononuclear cells from patients with systemic sclerosis and PAH but not in patients with systemic sclerosis and no PAH ([@bib11]), implying that the upregulation of mannose receptor in macrophages may contribute to PAH development. In the hope of developing imaging methods to distinguish between PAH and lung parenchymal diseases, such as interstitial lung disease, we are seeking to investigate the difference in the distribution patterns or the heterogeneity of lung ^68^Ga-NOTA-MSA uptake. Further studies are definitely needed to address the diagnostic specificity of ^68^Ga-NOTA-MSA PET for PAH. If these issues are resolved, the next step will be to demonstrate whether the use of ^68^Ga-NOTA-MSA PET can complement echocardiography or even right heart catheterization, hopefully to overcome the uncertainties of PAH diagnosis or prognosis in the future.
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